Rocket Pharmaceuticals (RCKT) Interest Coverage Ratio (2014 - 2026)
Rocket Pharmaceuticals (RCKT) posted Interest Coverage Ratio of 102.56 for Q1 2026, down 10.35% sequentially from 92.95 in Q4 2025, and up 24.82% YoY from 82.17 in Q1 2025.
Powered by 
Analysis
Rocket Pharmaceuticals (RCKT) Interest Coverage Ratio (2014 - 2026) Analysis & Trends
Rocket Pharmaceuticals has reported Interest Coverage Ratio for 13 years, with the latest figure at 102.56 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 24.82% year-over-year to 102.56 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 114.16 (up 20.28% YoY) and the FY2025 annual result came in at 1.74, up 17.73% from the prior year.
- Interest Coverage Ratio slipped to 102.56 in Q1 2026 per RCKT's latest filing, from 92.95 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 0.5 in Q1 2022 and troughed at 156.5 in Q2 2024.
- A 5-year average of 70.6 and a median of 92.95 in 2025 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2024 and 2025: Interest Coverage Ratio sank 28536.42% in 2024, then jumped 99.25% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 147.93 in 2022, then increased by 8.98% to 134.64 in 2023, then climbed by 1.55% to 132.55 in 2024, then advanced by 29.88% to 92.95 in 2025, then fell by 10.35% to 102.56 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 102.56, 92.95, and 1.1 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Rocket Pharmaceuticals | 437.27 Mn | 437.27 Mn | - | -99.20 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -99.20 |
| Mar 31, 2026 | -102.56 |
| Dec 31, 2025 | -92.95 |
| Sep 30, 2025 | -110.46 |
| Jun 30, 2025 | -150.42 |
| Mar 31, 2025 | -136.42 |
| Dec 31, 2024 | -132.55 |
| Sep 30, 2024 | -147.40 |
| Jun 30, 2024 | -156.50 |
| Mar 31, 2024 | -143.05 |
| Dec 31, 2023 | -134.64 |
| Sep 30, 2023 | -139.51 |
| Jun 30, 2023 | -146.92 |
| Mar 31, 2023 | -132.89 |
| Dec 31, 2022 | -147.93 |
| Sep 30, 2022 | -125.78 |
| Jun 30, 2022 | -116.58 |
| Mar 31, 2022 | -91.73 |
| Dec 31, 2021 | -95.75 |
| Sep 30, 2021 | -92.97 |